Mycofin is a preparation of terbinafine hydrochloride which is a synthetic allylamine derivative reported to have a broad spectrum of antifungal activity. It is considered to act through inhibition of fungal sterol synthesis. Mycofin is fungicidal against dermatophytes, and some yeasts, mold, fungi. It is the agent of choice for the treatment of dermatophyte nail infection.

• Onychomycosis of finger and toenails due to dermatophytes
• Ringworm infections (including Tinea pedis, cruris, and corporis) where oral therapy is appropriate (due to site, severity or extent)
• Dermatophyte infections of skin and hair 
• Non-dermatophyte nail infections
• Systemic mycoses with dimorphic and rare mold fungi

• For Tinea cruris: 250 mg tablet once daily
• for 2 to 4 weeks For Tinea pedis: 250 mg tablet once daily for 2 to 6 weeks
• For Tinea corporis: 250 mg tablet once daily for 4 weeks 
• For dermatophyte infections of the finger and toenails: 250 mg tablet once daily for 6 to 12 weeks. Longer treatment is necessary for toenail infections. 
• For skin and hair infections: 250 mg tablet once daily for 2 to 6 weeks depending on the severity and extent of the infection. 

Mycofin is contraindicated in patients with known hypersensitivity to terbinafine.

Mycofin should be used with caution in patients with impaired hepatic and renal function, pregnancy, breast-feeding.

Pregnancy: Although animal studies show no fetal toxicity, there are no information on possible adverse effects in human and it should not be given to pregnant women.
Nursing Mothers: Since the drug is excreted in breast milk, it should not be given to the nursing mothers.
Children: Not recommended.

Abdominal discomfort, anorexia, nausea, diarrhea; headache; rash and urticaria occasionally with arthralgia or myalgia; serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis reported (discontinue treatment if progressive skin rash). Taste disturbance, photosensitivity, and rarely liver toxicity (discontinue treatment) including jaundice, cholestasis and hepatitis also reported

Plasma concentrations of Mycofin may be increased by drugs that inhibit its metabolism by cytochrome P450, such as cimetidine, and decreased by drugs such as rifampicin that induce cytochrome P450.

Store in a cool, dry place, away from light. Keep out of reach of children.

Mycofin tablet: Box containing 1 strip of 10 tablets. Each tablet contains terbinafine hydrochloride INN equivalent to terbinafine 250mg. 



Manufactured by:
ESKAYEF BANGLADESH LTD
DHAKA, BANGLADESH
® REGD.TRADEMAR